Actinium Pharmaceuticals, Inc. (ATNM) - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated November 27, 2024, details the results of Actinium Pharmaceuticals, Inc.'s 2024 Annual Meeting of Stockholders. The filing addresses corporate governance matters, specifically the election of directors and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
At the Annual Meeting, 19,724,287 shares were present in person or by proxy out of 31,195,891 shares issued and outstanding as of the October 29, 2024 record date. All proposals were approved by stockholders:
- Election of Class II Directors: Sandesh Seth and Jeffrey W. Chell were elected to serve three-year terms expiring at the 2027 Annual Meeting.
- Ratification of Auditors: Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the final voting outcomes.
Investor Verification Checklist
- Verify the final voting tallies for Sandesh Seth and Jeffrey W. Chell against the company's definitive proxy statement.
- Confirm the term expiration dates for the newly elected Class II directors (2027).
- Review the Proxy Statement for detailed biographies of the elected directors and the rationale for the auditor ratification.
- Note that no financial performance data is included in this specific filing; refer to the most recent 10-K or 10-Q for financial metrics.